- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02178189
RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants
Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Infants exposed to methadone during pregnancy experience high rates of neonatal abstinence syndrome (NAS). Common NAS symptoms (tremulousness, increased muscle tone, sweating, excessive crying, vomiting and diarrhea) increase infants' metabolic needs. Another frequent NAS symptom, weak and uncoordinated suckling, impairs infants' ability to take in adequate calories. These combined problems compromise infant weight gain. The current standard of care for opiate-exposed infants requires evidence of poor weight gain or excessive weight loss before initiating high-calorie formula. We hypothesize that inadequate caloric intake among methadone exposed infants may result in excessive weight loss, slow weight regain and exacerbation of NAS. These factors lead to the newborn's requirement for higher morphine doses and longer duration of hospitalization. Therefore, methadone exposed infants may benefit from early caloric enhancement. A nutritional intervention for opiate-exposed infants has not been previously evaluated. This application will provide data on adequacy of recruitment, protocol feasibility, performance of selected measures, and preliminary estimates of efficacy for a comprehensive R01 submission.
Specific Aims:
For methadone exposed infants, compare infants randomized to high (24 kcal/oz) versus standard (20 kcal/oz) formula for the following outcomes:
- Weight loss and gain patterns. The primary dependent measure will be days until the infant returns to birth weight. Secondary measures will be maximum percent weight loss and days to weight nadir.
- NAS severity measured by: a) total length of hospital stay for NAS; b) duration of NAS treatment; c) mean Finnegan scores on days 2-10; d) maximum concentration of morphine used to treat NAS.
- Describe the suck quality at 4-6 days of age among methadone exposed infants. Evaluate the association between the infant suck quality and infant weight loss and gain patterns and measures of NAS severity.
Design: Women on methadone will be recruited during pregnancy and will attend a single brief visit late in pregnancy. After delivery, infants will be randomized in a double blind trial of either high-calorie or standard-calorie formula which will be started at 72 hours after birth and be continued through 21 days of age. Infants will be weighed daily and will have outpatient study visits at 1 and 3 months. For this pilot study, up to 70 mothers will be enrolled over 18 months. This pilot study is needed to establish the feasibility of the study methods and to better estimate differences that can be observed between the groups. For the primary outcome variable, days until the infant returns to birth weight, discrete survival methods will be used.
Potential Impact: Early caloric enhancement for methadone-exposed infants is inexpensive, readily available, easy to implement and could improve outcomes of these high-risk infants. High-calorie formula could result in a more normal pattern of weight loss and gain, less severe NAS symptoms and shorter hospital stays.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
PIttsburgh, Pennsylvania, United States, 15213
- Magee-Womens Hospital of UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants born to pregnant women, who are 18 to 45 years of age, participating in a licensed methadone maintenance treatment program
- planning to delivered at Magee if consented during pregnancy or delivered at Magee within the past 48 hours
Exclusion Criteria:
- Infants born weighing <2200 grams or before 35 weeks
- Multiple gestation pregnancies (eg. twins)
- Infants with major congenital malformations that could interfere with feeding or weight gain, such as Downs syndrome, cleft lip or palate, congenital heart disease or cystic fibrosis will be excluded.
- Infants admitted to the NICU longer than 48 hours for a medical condition other than treatment of NAS
- Women who do not speak English will be excluded because study staff will not be able to communicate effectively.
- Women who intend to place their infant for adoption
- Women who plan on feeding their baby soy formula from birth
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard-calorie infant formula
Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
|
Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
|
Experimental: High-calorie infant formula
Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
|
Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight Patterns (gain and loss)
Time Frame: Up to 3 weeks
|
Weight loss and gain patterns will include days to return to birth weight, days to weight nadir (lowest point) and maximum percent weight loss.
|
Up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neonatal abstinence syndrome (NAS) severity measures
Time Frame: Up to 3 weeks
|
NAS (Neonatal abstinence syndrome) severity can be measured in a few ways - for this study, we will use total length of hospital stay for NAS, duration of NAS treatment, mean Finnegan scores on days 3-10 and maximum concentration of morphine used to treat NAS
|
Up to 3 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Debra L Bogen, MD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO09120457
- R21DA029257 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Abstinence Syndrome
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA)RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Spark Biomedical, Inc.Medical University of South Carolina; University of Texas Southwestern Medical...RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Thomas Jefferson UniversityChiesi Farmaceutici S.p.A.CompletedNeonatal Abstinence Syndrome | Neonatal Opiate Withdrawal SyndromeUnited States
-
PediatrixCompletedNeonatal Abstinence Syndrome | Neonatal Withdrawal SyndromeUnited States
-
Tufts Medical CenterCompletedNeonatal Abstinence Syndrome | Neonatal Opioid WithdrawalUnited States
-
Tulane UniversityRecruitingNeonatal Abstinence Syndrome | Substance Withdrawal, NeonatalUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompletedOpioid-use Disorder | Neonatal Abstinence Syndrome | Opioid Withdrawal | Neonatal Opioid Withdrawal SyndromeUnited States
-
University of AlbertaAlberta Health services; Alberta Innovates Health Solutions; Covenant HealthRecruitingNeonatal Abstinence SyndromeCanada
-
University Hospital, CaenRecruitingNeonatal Abstinence SyndromeFrance
Clinical Trials on Standard Calorie Infant Formula
-
Société des Produits Nestlé (SPN)Completed
-
Société des Produits Nestlé (SPN)University College, LondonCompletedGrowth | Infant FormulaUnited Kingdom
-
Laboratorios OrdesaUnknownInfant DevelopmentSpain
-
Ludwig-Maximilians - University of MunichHiPP GmbH & Co. Vertrieb KGCompletedInfant NutritionGermany, Serbia
-
FrieslandCampinaTerminated
-
NestléNational University Hospital, SingaporeCompleted
-
Société des Produits Nestlé (SPN)Completed